Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer

American Journal of Pathology

Volumn 149, Issue 5, 1996, Pages 1435-1440

  Ueda, Takeshi ^a   Ichikawa, Tomohiko ^a   Tamaru, Jun Ichi ^a   Mikata, Atsuo ^a   Akakura, Koichiro ^a   Akimoto, Susumu ^a   Imai, Toshio ^b   Yoshie, Osamu ^b   Shiraishi, Taizo ^c   Yatani, Ryuichi ^c   Ito, Haruo ^d   Shimazaki, Jun ^a,c  

^a CHIBA UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Chiba University ^*

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN;

ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANTICARCINOGENIC AGENTS; ANTIGENS, CD; HUMANS; IMMUNOHISTOCHEMISTRY; KANGAI-1 PROTEIN; MALE; MEMBRANE GLYCOPROTEINS; PROSTATIC DISEASES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS;

EID: 10244279190     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Fearon ER, Vogelstein B: A gene model for colorectal turnorigenesis. Cell 1990, 61:759-767
2. Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thibodeau SN, Jenkins RB: Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 1995, 55:4114-4119
3. Nihei N, Ichikawa T, Kawana Y, Kuramochi H, Kugo H, Oshimura M, Killary AM, Rinker-Schaeffer CW, Barrett JC, Isaacs JT, Shimazaki J: Localization of metastatic suppressor gene(s) for rat prostate cancer to the long arm of human chromosome 10. Genes Chromosome Cancer 1995, 14:112-119
4. Ichikawa T, Nihei N, Suzuki H, Oshimura M, Emi M, Nakamura Y, Hayata I, Isaacs JT, Shimazaki J: Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8. Cancer Res 1994, 54: 2299-2302
5. Suzuki H, Emi M, Komiya A, Fujiwara Y, Yatani R, Nakamura Y, Shimazaki J: Localization of a tumor suppressor gene associated with progression of human prostate cancer within a 1.2 Mb region of 8p22-p21.3. Genes Chromosome Cancer 1995, 13:168-174
6. Bergerheim USR, Kunimi K, Collins VP, Ekman P: Deletion mapping of chromosome 8, 10, and 16 in human prostatic carcinoma. Genes Chromosome Cancer 1991, 3:215-220
7. Kunimi K, Bergerheim USR, Lasson IL, Ekman P, Collins VP: Allotyping of human prostatic adenocarcinoma. Genes Chromosomes & Cancer 1991, 11:530-536
8. Gao X, Honn KV, Grignon D, Sakr W, Chen YQ: Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res 1993, 53:2723-2727
9. Dong J-T, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC: KAI1, a metastatic suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995, 268:884-886
10. Fukudome K, Furuse M, Imai T, Nishimura M, Takagi S, Hinuma Y, Yoshie O: Identification of membrane antigen C33 recognized by monoclonal antibodies inhibitory to human T-cell leukemia virus type 1(HTLV-1)-induced syncytium formation: altered glycosylation of C33 antigen in HTLV-1-positive T cells. J Virol 1992, 66:1394-1401
11. Imai T, Fukudome K, Takagi S, Nagira M, Furuse M, Fukuhara N, Nishimura M, Himura Y, Yoshie O: C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63. J Immunol 1992, 149:2879-2886
12. Gleason DF: Classification of prostate carcinomas. Cancer Chemother Rep 1966, 50:125-128
13. Prout GR: Diagnosis and staging of prostatic carcinoma. Cancer (Phila) 1973, 32:1096-1103
14. Gaugitsch HW, Hofer E, Huber NE, Schnabl E, Baumruker T: A new superfamily of lymphoid and melanoma cell proteins with extensive homology to Schistosoma mansoni antigen Sm23. Eur J Immunol 1991, 21:377-383
15. Gil ML, Vita N, Lebel-Binay S, Miloux B, Chalon P, Kaghad M, Marchiol-Fournigault C, Conjeaud H, Caput D, Ferrara P, Fradelizi D, Quillet-Mary A: A member of tetra spans transmembrane protein superfamily is recognized by a monoclonal antibody raised against an HLA class I-deficient, lymphokine-activated killer-susceptible, B lymphocyte line. J Immunol 1992, 148: 2826-2833
16. Nojima Y, Hirose T, Tachibana K, Tanaka T, Shi L, Doshen J, Freeman GJ, Schlossman SF, Morimoto C: The 4F9 antigen is a member of the tetra spans transmembrane protein family and functions as an accessory molecule in T cell activation and adhesion. Cell Immunol 1993, 152:249-260
17. Horejsi V, Vleck C: Novel structurally distinct family of leukocyte surface glycoproteins including CD9, CD37, CD53, and CD63. FEBS Lett 1991, 288:1-4
18. Boucheix C, Benoit P, Frachet P, Billard M, Worthington RE, Gagnon J, Uzan G: Molecular cloning of the CD9 antigen. J Biol Chem 1991, 266:117-122
19. Oren R, Takahashi S, Doss C, Levy R, Levy S: TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol 1990, 10:4007-4015
20. Imai T, Yoshie O: C33 antigen and M38 antigen recognized by monoclonal antibodies inhibitory to syncytium formation by human T cell leukemia virus type 1 are both members of the transmembrane 4 superfamily and associate with each other and with CD4 or CD8 in T cells. J Immunol 1993, 151:6470-6481
21. Hotta H, Ross AH, Huebner K, Isobe M, Wendeborn S, Chao MV, Ricciardi RP, Tsujimoto Y, Croce CM, Koprowski H: Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res 1988, 48: 2955-2962
22. Miyake M, Nakano K, Ieki Y, Adachi M, Huang C-L, Itoi S, Koh T, Taki T: Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer. Cancer Res 1995, 55:4127-4131
23. Kondoh M, Ueda M, Ichihashi M, Mishima Y: Decreased expression of human melanoma-associated antigen ME491 along the progression of melanoma pre-canceroses to invasive and metastatic melanomas. Melanoma Res 1993, 3:241-245
24. Adachi M, Taki T, Ikei Y, Huang C-L, Higashiyama M, Miyake M: Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-cell lung cancer. Cancer Res 1996, 56:1751-1755
25. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HFM, Schaafsma HE, Debruyne FMJ, Isaacs WB: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992, 52:5104-5109
26. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HFM, Oosterhof GON, Debruyne FMJ, Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994, 54:3929-3933
27. Konishi N, Nakaoka S, Tsuzuki T, Matsumoto K, Kitahori Y, Hiasa Y, Urano T, Shiku H: Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma. Jpn J Cancer Res 1993, 84:1050-1054
28. Lesley J, Hyrnan R, Kincade PW: CD44 and its interaction with the extracellular matrix. Adv Immunol 1993, 54:271-335
29. Lokeshwar BL, Lokeshwar VB, Block NL: Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. Anticancer Res 1995, 15:1191-1198
30. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone Macaluso M: The TNM classification of prostate cancer. Prostate Suppl 1992, 4:129-138
31. Emrich LJ, Priore RL, Murphy GP, Brady MF, Investigators of the National Prostatic Cancer Project: Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 1985, 45:5173-5179
32. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988, 61:195-202
33. Takeda H, Akakura K, Masai M, Akimoto S, Yatani R, Shimazaki J: Androgen receptor content estimated by immunohistochemical staining is related to prognosis in stage D2 prostate cancer. Cancer 1996, 77:935-949